Veronique Groleau1, Joan I Schall, Virginia A Stallings, Christina A Bergqvist. 1. Division of Gastroenterology, Hepatology and Nutrition, Ste-Justine University Hospital Center, University of Montreal, Montreal, QC, Canada; Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Abstract
AIM: The long-term effects of the ketogenic diet, a high fat diet for treating intractable epilepsy, on resting energy expenditure (REE) are unknown. The aim of this study was to evaluate the impact of 15 months of ketogenic diet treatment on growth and REE in children with intractable epilepsy. METHOD: Growth, body composition, and REE were assessed at baseline, 3 months and 15 months in 24 children (14 males, 10 females; mean age 5 y 6 mo [SD 26 mo], range 7 mo-6 y 5 mo), 10 with cerebral palsy [CP]). Fifteen were identified as ketogenic diet responders at 3 months and continued on the ketogenic diet until 15 months. These were compared to 75 healthy children (43 males, 32 females; mean age 6 y 3 mo [SD 21 mo] age range 2-9 y). REE was expressed as percentage predicted, growth as height (HAz) and weight (WAz) z-scores, and body composition as fat and fat free mass (FFM). RESULTS: HAz declined -0.2 and -0.6 from baseline to 3 months and 15 months respectively (p = 0.001), while WAz was unchanged. In ketogenic diet responders, FFM, age and CP diagnosis predicted REE (overall R(2) = 0.76, p<0.001) and REE did not change. REE adjusted for FFM was lower (p<0.01) in children with CP at baseline (mean [standard error], -143[51] kcals/d) and 15 months (-198[53] kcals/d) compared to the healthy children. INTERPRETATION: After 15 months of the ketogenic diet, linear growth status declined while weight status and REE were unchanged. REE remained reduced in children with CP.
AIM: The long-term effects of the ketogenic diet, a high fat diet for treating intractable epilepsy, on resting energy expenditure (REE) are unknown. The aim of this study was to evaluate the impact of 15 months of ketogenic diet treatment on growth and REE in children with intractable epilepsy. METHOD: Growth, body composition, and REE were assessed at baseline, 3 months and 15 months in 24 children (14 males, 10 females; mean age 5 y 6 mo [SD 26 mo], range 7 mo-6 y 5 mo), 10 with cerebral palsy [CP]). Fifteen were identified as ketogenic diet responders at 3 months and continued on the ketogenic diet until 15 months. These were compared to 75 healthy children (43 males, 32 females; mean age 6 y 3 mo [SD 21 mo] age range 2-9 y). REE was expressed as percentage predicted, growth as height (HAz) and weight (WAz) z-scores, and body composition as fat and fat free mass (FFM). RESULTS: HAz declined -0.2 and -0.6 from baseline to 3 months and 15 months respectively (p = 0.001), while WAz was unchanged. In ketogenic diet responders, FFM, age and CP diagnosis predicted REE (overall R(2) = 0.76, p<0.001) and REE did not change. REE adjusted for FFM was lower (p<0.01) in children with CP at baseline (mean [standard error], -143[51] kcals/d) and 15 months (-198[53] kcals/d) compared to the healthy children. INTERPRETATION: After 15 months of the ketogenic diet, linear growth status declined while weight status and REE were unchanged. REE remained reduced in children with CP.
Authors: Elizabeth G Neal; Hannah M Chaffe; Nicole Edwards; Margaret S Lawson; Ruby H Schwartz; J Helen Cross Journal: Pediatrics Date: 2008-08 Impact factor: 7.124
Authors: C Beth Henderson; Francis M Filloux; Stephen C Alder; Joseph L Lyon; Deirdre A Caplin Journal: J Child Neurol Date: 2006-03 Impact factor: 1.987
Authors: Maximilian Bielohuby; Dominik Menhofer; Henriette Kirchner; Barbara J M Stoehr; Timo D Müller; Peggy Stock; Madlen Hempel; Kerstin Stemmer; Paul T Pfluger; Ellen Kienzle; Bruno Christ; Matthias H Tschöp; Martin Bidlingmaier Journal: Am J Physiol Endocrinol Metab Date: 2010-10-13 Impact factor: 4.310
Authors: A G Christina Bergqvist; Jillian Trabulsi; Joan I Schall; Virginia A Stallings Journal: Dev Med Child Neurol Date: 2008-04-17 Impact factor: 5.449
Authors: Kathryn M Camp; Danuta Krotoski; Melissa A Parisi; Katrina A Gwinn; Bruce H Cohen; Christine S Cox; Gregory M Enns; Marni J Falk; Amy C Goldstein; Rashmi Gopal-Srivastava; Gráinne S Gorman; Stephen P Hersh; Michio Hirano; Freddie Ann Hoffman; Amel Karaa; Erin L MacLeod; Robert McFarland; Charles Mohan; Andrew E Mulberg; Joanne C Odenkirchen; Sumit Parikh; Patricia J Rutherford; Shawne K Suggs-Anderson; W H Wilson Tang; Jerry Vockley; Lynne A Wolfe; Steven Yannicelli; Philip E Yeske; Paul M Coates Journal: Mol Genet Metab Date: 2016-09-20 Impact factor: 4.797
Authors: Colin P Hawkes; Sani M Roy; Bassem Dekelbab; Britney Frazier; Monica Grover; Jaime Haidet; James Listman; Sarianne Madsen; Marian Roan; Celia Rodd; Aviva Sopher; Peter Tebben; Michael A Levine Journal: J Clin Endocrinol Metab Date: 2021-01-23 Impact factor: 5.958
Authors: Charlotte Veyrat-Durebex; Pascal Reynier; Vincent Procaccio; Rudolf Hergesheimer; Philippe Corcia; Christian R Andres; Hélène Blasco Journal: Front Mol Neurosci Date: 2018-01-26 Impact factor: 5.639
Authors: Se Hee Kim; Alexandra Shaw; Robyn Blackford; Wesley Lowman; Linda C Laux; John J Millichap; Douglas R Nordli Journal: Sci Rep Date: 2019-06-19 Impact factor: 4.379
Authors: Jana Ruiz Herrero; Elvira Cañedo Villarroya; Juan José García Peñas; Beatriz García Alcolea; Begoña Gómez Fernández; Laura Andrea Puerta Macfarland; Consuelo Pedrón Giner Journal: Nutrients Date: 2020-01-24 Impact factor: 5.717